Regeneron Pharmaceuticals' Cash from Financing Activities rose 3129.9% to -$780.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$3.7 billion, marking a year-over-year decrease of 6884.34%. This contributed to the annual value of -$3.7 billion for FY2025, which is 6884.34% down from last year.
Latest data reveals that Regeneron Pharmaceuticals reported Cash from Financing Activities of -$780.1 million as of Q4 2025, which was up 3129.9% from -$717.9 million recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Cash from Financing Activities ranged from a high of $385.4 million in Q3 2021 and a low of -$1.1 billion during Q4 2024
Its 5-year average for Cash from Financing Activities is -$486.0 million, with a median of -$462.1 million in 2023.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Cash from Financing Activities skyrocketed by 11765.83% in 2022, and later crashed by 241252.65% in 2025.
Regeneron Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$906.6 million in 2021, then soared by 72.69% to -$247.6 million in 2022, then plummeted by 80.17% to -$446.1 million in 2023, then plummeted by 154.54% to -$1.1 billion in 2024, then surged by 31.3% to -$780.1 million in 2025.
Its Cash from Financing Activities stands at -$780.1 million for Q4 2025, versus -$717.9 million for Q3 2025 and -$1.1 billion for Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value